AI spending is surging so fast that even chip providers are paying double digit yields to secure hardware, as Anthropic's recent financing deal shows. That hunger for compute power filters directly into Australian healthcare companies using AI to read scans, sift medical records and speed up research. This article walks through three stocks from our AI driven healthcare screener that aim to turn that trend into long term portfolio exposure.
The stocks covered below are just a sample from this theme, and the full screen surfaced 4 more AI healthcare companies with equally detailed stories that are not discussed here. To see the wider field and identify which businesses fit your own thesis, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener .
ImExHS (ASX:IME)
Overview:ImExHS is a Sydney based health tech company that delivers cloud medical imaging software and radiology services that feed AI driven diagnostics.
Operations:ImExHS generates about A$10 million from software and A$21 million from radiology services, almost entirely from Latin America.
Market Cap:A$16.6 million
ImExHS matters for this AI healthcare theme because its imaging platforms and teleradiology services create the labeled scans AI tools rely on to spot disease earlier and streamline clinical workflows.
"They also understand the challenge now is to drive the software sales and revenue much faster in 2026."
The outlook for future margins and cash flow will likely depend on how one less visible pressure shapes that software heavy push.
That pressure point is exactly where the story gets interesting, so read the full narrative for ImExHS to see how ImExHS could turn that squeeze into accelerating software leverage.
Paragon Care (ASX:PGC)
Overview:Paragon Care supplies hospitals and clinics with AI enabled imaging systems, medical devices and consumables across Australia, New Zealand and Asia.
Operations:Paragon Care generates about A$3.5 billion from ANZ and A$160 million from Asia, with most revenue tied to Australia.
Market Cap:A$240 million
Paragon Care matters for this AI healthcare screen because its imaging and navigation portfolio puts AI supported diagnostics and surgical planning directly into clinical workflows.
"The integration of recent acquisitions and ongoing operational synergies (with a target of $12 million annual run-rate in FY '26), coupled with the consolidation of business functions onto a unified JDE platform, are likely to improve cost efficiencies and structurally enhance net margins and EBITDA."
For investors, the key consideration is whether that AI focused imaging arm gains enough traction to influence long term profitability.
If that shift really moves the needle on Paragon Care's earnings mix, the full narrative for Paragon Care shows how AI momentum and integration risks could be pulling in different directions.
Artrya (ASX:AYA)
Overview:Artrya is a West Perth based medtech business. Its Salix cloud software uses AI to analyse heart CT scans and flag coronary artery disease risk.
Operations:Artrya currently generates about A$0.03 million from developing its AI driven CCTA image analysis technology, all from Australia.
Market Cap:A$446.5 million
Artrya matters for this AI healthcare theme because Salix tackles one of cardiology's biggest problems: spotting dangerous coronary plaque early from routine imaging and turning that into decision ready risk scores for clinicians.
"Growing adoption of CCTA as a front-line tool for chest pain assessment, together with up to 400,000 scans a year across SAPPHIRE partners at a blended rate of about US$850 per scan across three modules, gives Artrya a clear volume pathway that directly targets future subscription and fee per scan revenue."
What affects the risk reward is how one evolving piece of evidence reshapes hospital confidence in paying for AI support at scale.
That tipping point is exactly what the full narrative for Artrya unpacks. It shows how Artrya's volume pathway could translate into accelerating adoption while still flagging where the risk may be stalling decisions.
Seeking Fresh Alternatives Before They Fly
Fresh opportunities do not stay quiet for long. Momentum builds, prices move, and the cleanest entry points can be taken quickly. Scan these under the radar ideas now to review them early.
-
Review steady cash generators before yields change by running the 4 dividend fortresses that focuses on durable payouts with potential for continued income.
-
Look for early breakout potential in sectors where balance sheets already appear robust by scanning the list of solid balance sheet and fundamentals (12 results) and filtering for businesses built to handle shocks.
-
Study the evolving wave of AI driven automation by reviewing the curated 91 robotics and automation stocks that highlights companies connecting machines, software and sensors.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
